CY1110385T1 - Χρηση αναστολεων της il-18 για τη θεραπεια και/ή προληψη της αθηροσκληρωσης - Google Patents

Χρηση αναστολεων της il-18 για τη θεραπεια και/ή προληψη της αθηροσκληρωσης

Info

Publication number
CY1110385T1
CY1110385T1 CY20081100684T CY081100684T CY1110385T1 CY 1110385 T1 CY1110385 T1 CY 1110385T1 CY 20081100684 T CY20081100684 T CY 20081100684T CY 081100684 T CY081100684 T CY 081100684T CY 1110385 T1 CY1110385 T1 CY 1110385T1
Authority
CY
Cyprus
Prior art keywords
atherosclerosis
prevention
treatment
inhibitors
medicament
Prior art date
Application number
CY20081100684T
Other languages
English (en)
Inventor
Yolande Chvatchko
Alain Tedgui
Ziad Mallat
Original Assignee
Laboratoires Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Serono Sa filed Critical Laboratoires Serono Sa
Publication of CY1110385T1 publication Critical patent/CY1110385T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

Η εφεύρεση αφορά στη χρήση ενός αναστολέα της IL-18 για την παρασκευή ενός φαρμακευτικού προϊόντος για την θεραπευτική αντιμετώπιση και/ή πρόληψη της αθηροσκλήρωσης.
CY20081100684T 2000-05-05 2008-06-30 Χρηση αναστολεων της il-18 για τη θεραπεια και/ή προληψη της αθηροσκληρωσης CY1110385T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00109606 2000-05-05
EP01945064A EP1278540B1 (en) 2000-05-05 2001-04-30 Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis

Publications (1)

Publication Number Publication Date
CY1110385T1 true CY1110385T1 (el) 2015-04-29

Family

ID=8168631

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100684T CY1110385T1 (el) 2000-05-05 2008-06-30 Χρηση αναστολεων της il-18 για τη θεραπεια και/ή προληψη της αθηροσκληρωσης

Country Status (33)

Country Link
US (1) US20040076628A1 (el)
EP (1) EP1278540B1 (el)
JP (1) JP5122053B2 (el)
KR (2) KR100798545B1 (el)
CN (2) CN1250286C (el)
AR (1) AR035640A1 (el)
AT (1) ATE395075T1 (el)
AU (2) AU6739001A (el)
BG (1) BG65881B1 (el)
BR (1) BRPI0110506B8 (el)
CA (1) CA2407895C (el)
CY (1) CY1110385T1 (el)
CZ (1) CZ300792B6 (el)
DE (1) DE60134009D1 (el)
DK (1) DK1278540T3 (el)
EA (2) EA007014B1 (el)
EE (1) EE05056B1 (el)
ES (1) ES2305082T3 (el)
HK (2) HK1055681A1 (el)
HR (1) HRP20020828A2 (el)
HU (1) HU229375B1 (el)
IL (2) IL152567A0 (el)
ME (1) ME00554B (el)
MX (1) MXPA02010895A (el)
NO (1) NO329821B1 (el)
PL (1) PL209371B1 (el)
PT (1) PT1278540E (el)
RS (1) RS50926B (el)
SI (1) SI1278540T1 (el)
SK (1) SK287761B6 (el)
UA (2) UA87658C2 (el)
WO (1) WO2001085201A2 (el)
ZA (1) ZA200208228B (el)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2399148A1 (en) * 2000-02-10 2001-08-16 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
CA2435466C (en) * 2001-01-29 2012-04-03 Applied Research Systems Ars Holding N.V. Use of il-18 inhibitors for the treatment and/or prevention of heart disease
CA2445664C (en) * 2001-05-25 2012-03-06 Ares Trading S.A. Use of il-18 inhibitors for treating or preventing cns injuries
US6797727B2 (en) 2001-07-16 2004-09-28 Transition Therapeutics Inc. Use of rhein or diacerhein compounds for the treatment or prevention of vascular diseases
GB0210212D0 (en) * 2002-05-03 2002-06-12 Univ Southampton Effects of dietary N-3 and N-6 pufa intake on atheromatous plaque stability
US8729124B2 (en) 2002-03-05 2014-05-20 Pronova Biopharma Norge As Use of EPA and DHA in secondary prevention
PT1487541E (pt) * 2002-03-22 2008-12-10 Inst Nat Sante Rech Med Utilização de inibidores de il-8 para o tratamento e/ou prevenção de doenças vasculares periféricas
ATE399872T1 (de) * 2003-03-11 2008-07-15 Serono Lab Expressionvektoren, die den promotor des ie2-gens des maus cytomegalovirus enthalten
EP1622939B1 (en) 2003-05-13 2012-03-14 Merck Serono SA Active variants of the il-18 binding protein and medical uses thereof
US7968684B2 (en) * 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
US20080044404A1 (en) * 2004-04-15 2008-02-21 Anna Cederholm Annexin V for Preventing Atherothrombosis and Plaque Rupture
CN101219208B (zh) * 2005-01-04 2010-08-11 健能隆医药技术（上海）有限公司 白介素-22的医药用途
PT1885753E (pt) 2005-06-03 2011-10-06 Ares Trading Sa Produção de proteína recombinante de ligação a il-18
WO2006131550A1 (en) 2005-06-10 2006-12-14 Ares Trading S.A. Process for the purification of il-18 binding protein
AR082518A1 (es) 2010-08-25 2012-12-12 Hoffmann La Roche Anticuerpos contra il-18r1 y usos de los mismos
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
MD707Z (ro) * 2013-01-18 2014-07-31 Институт Зоологии Академии Наук Молдовы Metodă de identificare a secvenţelor polimorfe 4a/4b ale genei sintetazei endoteliale a oxidului nitric
SG11201601717VA (en) 2013-09-05 2016-04-28 Ab2 Bio Sa Il-18 binding protein (il-18bp) in inflammatory diseases
CN107660150B (zh) 2015-03-05 2023-10-24 Ab2生物股份有限公司 Il-18结合蛋白(il-18bp)和抗体在炎性疾病中
CN110273591B (zh) 2019-08-13 2023-12-12 上海杉脉电子科技发展有限公司 一种单动力微型智能锁
TW202233675A (zh) 2020-10-29 2022-09-01 瑞士商諾華公司 Ｉｌ－１８拮抗劑用於治療和／或預防異位性皮炎或相關病症之用途
CN112972655A (zh) * 2021-04-16 2021-06-18 武汉大学 白细胞介素12在制备预防、缓解和/或治疗主动脉瘤药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985863A (en) * 1996-09-12 1999-11-16 Vertex Pharmaceuticals, Inc. Compositions and methods for decreasing IGIF and IFN-γ production by administering an ICE inhibitor
US5877197A (en) * 1996-12-16 1999-03-02 Karanewsky; Donald S. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
EP0987552A3 (en) * 1998-08-31 2000-06-07 Pfizer Products Inc. Diarylsulfonylurea binding proteins
WO2000012555A1 (fr) * 1998-09-01 2000-03-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Proteine de liaison de l'interleukine 18

Also Published As

Publication number Publication date
BRPI0110506B1 (pt) 2015-05-19
EE200200620A (et) 2004-06-15
MXPA02010895A (es) 2003-03-27
UA87658C2 (uk) 2009-08-10
CZ300792B6 (cs) 2009-08-12
EA007014B1 (ru) 2006-06-30
HUP0301991A3 (en) 2006-11-28
NO20025307L (no) 2002-12-18
EA005410B1 (ru) 2005-02-24
MEP64008A (en) 2011-12-20
SI1278540T1 (sl) 2008-10-31
CZ20023644A3 (cs) 2003-03-12
CN1841066B (zh) 2012-08-29
JP2003532685A (ja) 2003-11-05
DK1278540T3 (da) 2008-07-21
HUP0301991A2 (hu) 2003-09-29
KR20030016254A (ko) 2003-02-26
ZA200208228B (en) 2005-07-27
BRPI0110506B8 (pt) 2021-05-25
HK1055681A1 (en) 2004-01-21
AR035640A1 (es) 2004-06-23
CN1250286C (zh) 2006-04-12
EE05056B1 (et) 2008-08-15
CA2407895A1 (en) 2001-11-15
HU229375B1 (en) 2013-11-28
ATE395075T1 (de) 2008-05-15
ES2305082T3 (es) 2008-11-01
IL152567A (en) 2010-12-30
KR100798545B1 (ko) 2008-01-28
PT1278540E (pt) 2008-07-03
SK287761B6 (en) 2011-09-05
UA78492C2 (en) 2007-04-10
JP5122053B2 (ja) 2013-01-16
AU2001267390B2 (en) 2005-09-22
US20040076628A1 (en) 2004-04-22
NO20025307D0 (no) 2002-11-05
SK15562002A3 (sk) 2003-05-02
PL209371B1 (pl) 2011-08-31
EA200401183A1 (ru) 2004-12-30
BG107218A (bg) 2003-06-30
EA200201175A1 (ru) 2003-04-24
CN1841066A (zh) 2006-10-04
IL152567A0 (en) 2003-05-29
YU82602A (sh) 2006-01-16
RS50926B (sr) 2010-08-31
CA2407895C (en) 2012-12-18
BG65881B1 (bg) 2010-04-30
PL365697A1 (en) 2005-01-10
NO329821B1 (no) 2010-12-27
BR0110506A (pt) 2003-04-01
CN1434722A (zh) 2003-08-06
HK1094909A1 (en) 2007-04-13
WO2001085201A2 (en) 2001-11-15
AU6739001A (en) 2001-11-20
EP1278540A2 (en) 2003-01-29
HRP20020828A2 (en) 2004-12-31
EP1278540B1 (en) 2008-05-14
WO2001085201A3 (en) 2002-05-10
ME00554B (me) 2012-03-20
KR20070073989A (ko) 2007-07-10
DE60134009D1 (de) 2008-06-26

Similar Documents

Publication Publication Date Title
CY1110385T1 (el) Χρηση αναστολεων της il-18 για τη θεραπεια και/ή προληψη της αθηροσκληρωσης
CY1116992T1 (el) Μεθοδος θεραπειας της σκληρυνσης κατα πλακας αναστελλοντας τη δραση της il-17
CY1108725T1 (el) Συνδυασμος ανταγωνιστου-nmda και αναστολεων ακετυλοχολινεστερασης δια την θεραπειαν της νοσου alzheimer
CY2022009I1 (el) Διυδροναφθυριδινες και σχετικες ενωσεις χρησιμες ως αναστολεις κινασης για τη θεραπεια πολλαπλασιαστικων ασθενειων
CY1108748T1 (el) Χρηση αναστολεων της il-18 για την αντιμετωπιση και/η προληψη περιφερικων αγγειακων παθησεων
WO2003042246A3 (en) Inhibitors of the notch signalling pathway for use in the treatment of cancer
CY1107424T1 (el) Χρηση ενος αναστολεα ibat για τη θεραπευτικη αντιμετωπιση η προφυλαξη απο δυσκοιλιοτητα
CY2013043I1 (el) Ενωσεις 4-οξοκινολινης και χρησιμοποιηση αυτων ως αναστολεις της ενσωματασης του hiv
DE60202452D1 (de) Pyridazinonaldose reductase inhibitoren
NO20034042D0 (no) Metallproteinase-inhibitorer
CY1109814T1 (el) Ενας συνδυασμος που περιεχει candesartan και rosuvastatin για τη θεραπευτικη αντιμετωπιση της αρτηριοσκληρυνσης
NO20034032L (no) Metallproteinase-inhibitorer
CY1107203T1 (el) Χρηση αναστολεων της il - 18 για τη θεραπεια και/ή την προληψη καρδιακης νοσου
ATE273699T1 (de) Pharmazeutische verbindungen zur behandlung von chronisch-obstruktiver bronchopneumonie
NO20042916L (no) HIV integrase inhibitorer
HUP0401854A2 (hu) COX-2 inhibitorokat és aszpirint tartalmazó kombinációk
ATE469886T1 (de) 17beta-hydroxysteroid dehydrogenase typ-3 hemmer zur behandlung von androgen abhängigen erkrankungen
CY1116137T1 (el) Χρηση των αναστολεων il-18 σε διαταραχες υπερευαισθησιας
FI20000635A0 (fi) COMT-inhibiittoreiden käyttö analgeettina
ECSP034634A (es) Inhibidores de la farnesil transferasa
NO20043114L (no) Bredspektrede heterocyklisk substituerte fenylinneholdende sulfonamid-HIV-proteaseinhibitorer
SE0301883D0 (sv) New use II
ATE374203T1 (de) Therapeutische verbindungen und verfahren
EE05263B1 (et) IL-18 inhibiitorite kasutamine keskn„rvissteemi kahjustuste raviks v?i ennetamiseks
SE0004827D0 (sv) Therapeutic compounds